Amstutz, A., Speich, B., Mentré, F., Rueegg, C. S., Belhadi, D., Assoumou, L., Burdet, C., et al. (2023). Effects of remdesivir in patients hospitalised with COVID-19: A systematic review and individual patient data meta-analysis of randomised controlled trials. The Lancet Respiratory Medicine, 11(5), 453-464.
Beigel, J. H., Tomashek, K. M., Dodd, L. E., Mehta, A. K., Zingman, B. S., Kalil, A. C., Hohmann, E., et al. (2020). Remdesivir for the treatment of COVID-19: Final report. ACTT-1 Study Group. The New England Journal of Medicine, 383(19), 1813-1826.
Boglione, L., Dodaro, V., Meli, G., Rostagno, R., Poletti, F., Moglia, R., Bianchi, B., Esposito, M., & Borrè, S. (2022). Remdesivir treatment in hospitalized patients affected by COVID-19 pneumonia: A case-control study. Journal of Medical Virology, 94(8), 3653-3660. https://doi.org/10.1002/jmv.27768
Copenhagen Economics. (2023). The impact of Remdesivir in the European Union. [See link].
Czernichow, S., Bain, S. C., Capehorn, M., Bøgelund, M., Madsen, M. E., Yssing, C., McMillan, A. C., Cancino, A.‐P., and Panton, U. H. (2021). Costs of the COVID‐19 pandemic associated with obesity in Europe: A health‐care cost model. Clinical Obesity 11, e12442.
Dobrowolska, K., Zarębska-Michaluk, D., Brzdęk, M., Rzymski, P., Rogalska, M., Moniuszko-Malinowska, A., Kozielewicz, D., et al. (2023). Retrospective analysis of the effectiveness of remdesivir in COVID-19 treatment during periods dominated by Delta and Omicron SARS-CoV-2 variants in clinical settings. Journal of Clinical Medicine, 12(6), 2371. https://doi.org/10.3390/jcm12062371
Gomes JJF, Gomes MC. Tempos de estadia hospitalar dos doentes COVID e projecções para a ocupação hospitalar COVID. Faculdade de Ciências, Universidade Lisboa. 2020.
Gottlieb, R. L., Vaca, C. E., Paredes, R., Mera, J., Webb, B. J., Perez, G., Oguchi, G., et al. (2022). Early remdesivir to prevent progression to severe COVID-19 in outpatients. The New England Journal of Medicine, 386(4), 305-315. https://doi.org/10.1056/NEJMoa2116846
Lau, V. I., Fowler, R., Pinto, R., Tremblay, A., Borgia, S., Carrier, F. M., Cheng, M. P., et al. (2022). Cost-effectiveness of remdesivir plus usual care versus usual care alone for hospitalized patients with COVID-19: An economic evaluation as part of the Canadian Treatments for COVID-19 (CATCO) randomized clinical trial. Canadian Medical Association Open Access Journal, 10(3), E807-E817.
Marocco, R., Del Borgo, C., Tortellini, E., Garattini, S., Carraro, A., Di Trento, D., Gasperin, A., et al. (2023). Use of remdesivir in patients with SARS-CoV-2 pneumonia in a real-life setting during the second and third COVID-19 epidemic waves. Viruses, 15(4), 947. https://doi.org/10.3390/v15040947
Marx, K., Gončarova, K., Fedders, D., Kalbitz, S., Kellner, N., Fedders, M., & Lübbert, C. (2023). Clinical outcomes of hospitalized COVID-19 patients treated with remdesivir: A retrospective analysis of a large tertiary care center in Germany. Infection, 51(1), 97-108.
Our World in Data. (2024). Portugal: Coronavirus Pandemic Country Profile. [See link].
Russo, A., Binetti, E., Borrazzo, C., Cacciola, E. G., Battistini, L., Ceccarelli, G., Mastroianni, C. M., & d’Ettorre, G. (2021). Efficacy of remdesivir-containing therapy in hospitalized COVID-19 patients: A prospective clinical experience. Journal of Clinical Medicine, 10(17), 3784. https://doi.org/10.3390/jcm10173784
Veronese, N., Di Gennaro, F., Frallonardo, L., Ciriminna, S., Papagni, R., Carruba, L., Agnello, D., et al. (2024). Real-life experience on the use of remdesivir in patients admitted to COVID-19 in two referral Italian hospitals: A propensity score-matched analysis. Scientific Reports, 14(1), 9303. https://doi.org/10.1038/s41598-024-59957-w
If you want to know more about our Healthcare & Life Sciences service, click on the link below.
